Recent Finacing
Recent Raise
Illexcor Therapeutics is developing ILX002, an oral Hemoglobin S–binding drug that blocks polymerization and sickling; the lead is in preclinical development with clinical trials planned and partnered with Zynext.
Focus Areas
Recent Investors
Funding round
Investor
See the team members at Illexcor Therapeutics.
